Molteni Therapeutics Receives CE Mark for Its New Product VULNOFAST® plus

Florence, December 2014

Florence (Italy) – Molteni Therapeutics Srl announced that it received CE Mark* approval for its new product VULNOFAST^® plus. VULNOFAST^® plus is an improved formulation to facilitate use, increase stability and reduce costs of VULNOFAST^® gel, maintaining the top-level quality standards of the original product. The product is sterile and presented in easy-to-use plastic monodose containers. VULNOFAST^® plus is a medical device intended for topical application to be used as adjuvant for the local treatment of cutaneous ulcers and lesions by means of photodynamic therapy.

* The CE Mark indicates that the product satisfies requirements of EU Directives (EU：The European Union) and all products need to be CE certified to be sold in Europe.